Q-omics provides the consensus-scored CASQ2 profile across patient tissues and cancer cell-line models. CASQ2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CASQ2 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, CASQ2 RNA expression shows 21,813 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, BLCA, and LUAD as cancer lineages where CASQ2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CASQ2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CASQ2 survival associations across molecular data types. CASQ2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CASQ2 RNA expression–survival associations across cancer types. High CASQ2 expression shows unfavorable associations in BLCA, HNSC, UVM and KIRP, but favorable associations in KIRC and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CASQ2 RNA expression.
This table summarizes CASQ2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CASQ2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CASQ2 shows lower tumor expression in BLCA, LUAD, THCA, COAD, KICH and LUSC. The BLCA box plot shows higher CASQ2 RNA expression in normal versus tumor tissue (log2 FC = −6.182, t-test p < 0.001).
This table shows molecular features associated with CASQ2 in patient tissues and cancer cell lines. In patient samples, CASQ2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CASQ2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SOFT_TISSUE.
